In a recently published commentary that has stirred significant discussion in the oncology research community, Hercent, Mary, and Tchernitchko critically evaluate the findings presented by Skarin Nordenvall and colleagues regarding the risk of malignant melanoma and colorectal cancer in patients with Birt-Hogg-Dubé (BHD) syndrome. Their publication, featured in the prestigious British Journal of Cancer in June 2026, underscores the multifaceted challenges of correlating rare genetic syndromes with increased cancer risk, revealing nuances that could reshape future diagnostic and therapeutic approaches.
Birt-Hogg-Dubé syndrome, a seldom diagnosed genetic disorder marked by mutations in the folliculin (FLCN) gene, has conventionally been associated with benign skin manifestations, pulmonary cysts, and a predisposition to kidney neoplasms. However, recent epidemiological investigations have aimed to unravel potential links between BHD syndrome and elevated risks of other malignancies, notably malignant melanoma and colorectal cancer. The initial matched cohort study by Skarin Nordenvall et al. sought to clarify these associations with a rigorous comparison between BHD patients and matched controls.
Hercent and colleagues’ critique pivots around the methodological frameworks employed in the original study, particularly highlighting the statistical models and the data interpretation strategies. They express concerns that the matching criteria, although stringent, might not fully account for environmental or lifestyle confounders that profoundly influence melanoma and colorectal cancer risks. This methodological scrutiny is pivotal, as overlooking such factors could lead to overestimated risk projections linked to BHD syndrome.
Within their commentary, the authors delve deeper into the molecular and genetic underpinnings of BHD syndrome, emphasizing the folliculin protein’s role in cellular pathways such as mTOR signaling, energy sensing, and cellular metabolism. Intriguingly, they argue that while aberrations in these pathways may drive tumorigenesis in renal tissues, the extrapolation of such mechanisms to melanoma and colorectal epithelial cells necessitates more robust experimental validation. This perspective invites a reconsideration of assumed pathophysiological commonalities that have shaped prior risk assessments.
The discussion extends to an exploration of melanocyte biology and colorectal mucosal dynamics within the context of BHD-related folliculin dysfunction. Melanocytes exhibit distinct vulnerabilities to UV-induced damage, and the commentary questions whether folliculin mutations potentiate this susceptibility or if observed melanoma incidences are attributable to stochastic genetic events coinciding with BHD diagnosis. Similarly, the commentary critiques the aggregation of colorectal cancer cases, suggesting that these may reflect broader genetic or lifestyle predispositions rather than direct consequences of folliculin haploinsufficiency.
Hercent et al. underscore the importance of integrating multi-omics approaches to dissect the complex interplay between genetic predispositions and tumor microenvironments. They advocate for advanced single-cell transcriptomics and proteomics studies to elucidate folliculin’s exact influence within diverse cellular populations implicated in melanoma and colorectal carcinogenesis. Such granular investigation could illuminate subtle mechanistic variations that natural history studies fail to capture.
Moreover, the commentary addresses the practical implications of screening recommendations arising from the initial study. Given the potential for overdiagnosis or misclassification of risk in BHD patients, Hercent and colleagues call for refined clinical guidelines that balance vigilance with the avoidance of unnecessary interventions. Their critique encompasses an evaluation of current dermatological and gastroenterological surveillance protocols, urging a tailored strategy informed by more precise biomarkers.
They also probe the genetic heterogeneity inherent in BHD syndrome, noting that variant-specific phenotypic presentations might modulate cancer risk profiles. This observation aligns with emerging paradigms in precision oncology and genetics, where single-gene disorders reveal complex, genotype-dependent cancer susceptibilities. Comprehensive genotype-phenotype correlation studies are posited as essential to unravel this complexity.
Importantly, the commentary situates the debate within the broader public health context, cautioning against amplified alarmism surrounding rare syndromes without conclusive evidence. They emphasize that while vigilance is necessary, balanced communication with patients and clinicians is paramount to mitigate undue anxiety and resource misallocation.
Throughout their analysis, Hercent and team commend aspects of the original cohort study, such as its sizeable sample and robust follow-up duration, which set a high standard for rare disease epidemiology. Yet, they underscore that scientific progress mandates continuous reassessment of conclusions as new data and analytical tools emerge.
Their final remarks advocate for collaborative, interdisciplinary research efforts that integrate clinical insights with advanced molecular biology to fully elucidate cancer risks in BHD syndrome. By fostering such integrative approaches, the medical community can better delineate genuine risk factors from coincidental findings, ultimately improving patient care and outcomes.
This commentary exemplifies the critical role of post-publication peer evaluation in refining our understanding of genetic syndromes and their oncogenic potential. As research technologies evolve, so too must our frameworks for interpreting genetic risks, ensuring that patients with rare conditions receive evidence-based, nuanced clinical guidance. The dialogue ignited by Hercent, Mary, and Tchernitchko not only enriches the BHD research landscape but also exemplifies the dynamic nature of scientific inquiry itself.
Subject of Research: Cancer risk assessment in Birt-Hogg-Dubé (BHD) syndrome, specifically focusing on malignant melanoma and colorectal cancer.
Article Title: Comment on “Risk of malignant melanoma and colorectal cancer in Birt-Hogg-Dubé syndrome—a matched cohort study” by Skarin Nordenvall et al.
Article References:
Hercent, A., Mary, M. & Tchernitchko, D. Comment on “Risk of malignant melanoma and colorectal cancer in Birt-Hogg-Dubé syndrome—a matched cohort study” by Skarin Nordenvall et al. Br J Cancer (2026). https://doi.org/10.1038/s41416-026-03500-3
Image Credits: AI Generated
DOI: 10.1038/s41416-026-03500-3
Tags: Birt-Hogg-Dubé syndrome cancer riskcolorectal cancer and genetic syndromesdiagnostic challenges in rare genetic cancersenvironmental factors in genetic cancer riskepidemiological studies on BHD syndromefolliculin gene mutations and cancermalignant melanoma risk in BHD patientsmatched cohort studies in cancer riskmethodological critique in cancer researchrare genetic disorders and oncologystatistical models in oncology researchtherapeutic approaches for BHD-related cancers
